The US Food and Drug Administration’s approval of Johnson & Johnson’s third-generation EGFR inhibitor Lazcluze (lazertinib) for use with Rybrevant (amivantamab-vmjw) represents a potential challenge to the dominant position of AstraZeneca PLC’s Tagrisso (osimertinib) in first-line treatment of non-small cell lung cancer (NSCLC) patient with some EGFR mutations.
However, despite the combination showing better efficacy, Tagrisso may maintain its dominant position until J&J can iron out the safety issues of its offering, which it
Key Takeaways
-
The FDA approved J&J’s small molecule Lazcluze for use in combination with its bispecific antibody Rybrevant for NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations.
-
The approval sets up the combination as a competitor to the current standard of care, AstraZeneca’s single-agent Tagrisso, with superior efficacy shown in the MARIPOSA trial
